In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
|Slideshows|March 20, 2021
Understanding the American Heart Association's Scientific Statement on Brain Health
Author(s)Gregory M. Weiss, MD
Just ahead of the International Stroke Conference, the AHA released a scientific statement focusing on brain health and aimed at providing primary care providers an overview of factors influencing neurologic health.
Advertisement
Advertisement
Related to this article
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Trending on HCPLive
1
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
2
Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD
3
8 Pulmonology Headlines You Missed in Q3 2026
4
EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis
5